ACTG A5202 (VS 10): TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RITONAVIR

ACTG A5202（VS 10）：开放标签依非韦伦或阿扎那韦与利托那韦的试验

• 批准号: 7604455
• 负责人: THOMAS A CAMPBELL
• 金额: $ 28.42万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-07-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604455
• 关键词: AIDS clinical trial group; Anti-HIV Agents; Atazanavir; Computer Retrieval of Information on Scientific Projects Database; Drug Combinations; Funding; Grant; HIV; Institution; Label; Lamivudine; Pharmaceutical Preparations; Research; Research Personnel; Resources; Ritonavir; Safety; Source; Tenofovir; United States Food and Drug Administration; United States National Institutes of Health; abacavir; compare effectiveness; efavirenz; emtricitabine

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is being done to compare the effectiveness, safety, and tolerability of anti-HIV drug combinations. The following drugs and drug combinations will be used in this study: " Efavirenz (EFV) with emtricitabine (FTC) and tenofovir (TDF) " EFV with abacavir (ABC) and lamivudine (3TC) " Atazanavir (ATV) with ritonavir (RTV) and FTC/TDF " ATV with RTV and ABC/3TC All of the drugs are approved by the FDA for treating HIV.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究是为了比较抗HIV药物组合的有效性、安全性和耐受性。这项研究将使用以下药物和药物组合： Efavirenz(EFV)与恩曲他滨(FTC)和替诺福韦(TDF) “使用阿巴卡韦(ABC)和拉米夫定(3TC)的EFV “阿扎那韦(ATV)联合利托那韦(RTV)和FTC/TDF “有RTV和ABC/3TC的亚视 所有这些药物都得到了FDA的批准，用于治疗艾滋病毒。